Pharmacological Stimulation of NADH Oxidation Ameliorates Obesity and Related Phenotypes in Mice
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Nicotinamide adenine dinucleotides (NAD+ and NADH) play a crucial role in cellular energy metabolism, and a dysregulated NAD+-to-NADH ratio is implicated in metabolic syndrome. However, it is still unknown whether a modulating intracellular NAD+-to-NADH ratio is beneficial in treating metabolic syndrome. We tried to determine whether pharmacological stimulation of NADH oxidation provides therapeutic effects in rodent models of metabolic syndrome. RESEARCH DESIGN AND METHODS: We used β-lapachone (βL), a natural substrate of NADH:quinone oxidoreductase 1 (NQO1), to stimulate NADH oxidation. The βL-induced pharmacological effect on cellular energy metabolism was evaluated in cells derived from NQO1-deficient mice. In vivo therapeutic effects of βL on metabolic syndrome were examined in diet-induced obesity (DIO) and ob/ob mice. RESULTS: NQO1-dependent NADH oxidation by βL strongly provoked mitochondrial fatty acid oxidation in vitro and in vivo. These effects were accompanied by activation of AMP-activated protein kinase and carnitine palmitoyltransferase and suppression of acetyl-coenzyme A (CoA) carboxylase activity. Consistently, systemic βL administration in rodent models of metabolic syndrome dramatically ameliorated their key symptoms such as increased adiposity, glucose intolerance, dyslipidemia, and fatty liver. The treated mice also showed higher expressions of the genes related to mitochondrial energy metabolism (PPARγ coactivator-1α, nuclear respiratory factor-1) and caloric restriction (Sirt1) consistent with the increased mitochondrial biogenesis and energy expenditure. CONCLUSIONS: Pharmacological activation of NADH oxidation by NQO1 resolves obesity and related phenotypes in mice, opening the possibility that it may provide the basis for a new therapy for the treatment of metabolic syndrome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Abdominal obesity and metabolic syndrome
Després, J.-P., & Lemieux, I. (2006) · Nature · doi:10.1038/nature05488 · Cited by 4,354 · cited 1×
“It has been reported that the imbalance between energy intake and expenditure is clearly related to obesity and metabolic disorders (2).”
BackgroundResveratrol improves health and survival of mice on a high-calorie diet
Baur, J. A., Pearson, K. J., Price, N. L., Jamieson, H. A., Lerin, C., Kalra, A., Prabhu, V. V., Allard, J. S., Lopez-Lluch, G., Lewis, K., et al. (2006) · Nature · doi:10.1038/nature05354 · Cited by 4,290
Lagouge, M., Argmann, C., Gerhart-Hines, Z., Meziane, H., Lerin, C., Daussin, F., Messadeq, N., Milne, J., Lambert, P., Elliott, P., et al. (2006) · Cell · doi:10.1016/j.cell.2006.11.013 · Cited by 4,057 · cited 1×
“Mitochondrial dysfunctions are frequently associated with obesity and diabetes, and improvements in obesity and glucose tolerance are associated with enhanced mitochondrial oxphos functions and biogenesis (47,48).”
BackgroundKahn, B. B., Alquier, T., Carling, D., & Hardie, D. G. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2004.12.003 · Cited by 2,799
Metabolic control through the PGC-1 family of transcription coactivators
Lin, J., Handschin, C., & Spiegelman, B. M. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.05.004 · Cited by 2,130 · cited 7×
“Calorie restriction (4) and increased physical activity, in fact, have been known to prevent and reverse the phenotypes of metabolic syndrome by activating metabolic regulator proteins such as Sirt1, AMP-activated protein kinase (AMPK), and PPAR coactivator-1 (PGC-1 ) (5–8).”
InfluentialCalorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase
Cohen, H. Y., Miller, C., Bitterman, K. J., Wall, N. R., Hekking, B., Kessler, B., Howitz, K. T., Gorospe, M., de Cabo, R., & Sinclair, D. A. (2004) · Science · doi:10.1126/science.1099196 · Cited by 1,924
Towards a molecular understanding of adaptive thermogenesis
Lowell, B. B., & Spiegelman, B. M. (2000) · Nature · doi:10.1038/35007527 · Cited by 1,630 · cited 1×
“mitochondrial remodeling and biogenesis (34,39,40), we examined the physiological and ultrastructural changes of mitochondria in L-treated DIO mice.”
BackgroundHawley, S. A., Pan, D. A., Mustard, K. J., Ross, L., Bain, J., Edelman, A. M., Frenguelli, B. G., & Hardie, D. G. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.05.009 · Cited by 1,589
Ying, W. (2008) · Antioxidants & Redox Signaling · doi:10.1089/ars.2007.1672 · Cited by 1,494
Cited by
Price, N. L., Gomes, A. P., Ling, A. J. Y., Duarte, F. V., Martin-Montalvo, A., North, B. J., Agarwal, B., Ye, L., Ramadori, G., Teodoro, J. S., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.04.003 · Cited by 1,602
“, 2009; Wallace, 2005) and that treatments that stimulate mitochondrial function can delay the progression of some of these diseases (Baur et al., 2006; Fillmore et al., 2010; Horvath et al., 2011; Hwang et al., 2009; Lagouge et al., 2006; Wenz et al., 2009).”
BackgroundSirtuin 1 and Sirtuin 3: Physiological Modulators of Metabolism
Nogueiras, R., Habegger, K. M., Chaudhary, N., Finan, B., Banks, A. S., Dietrich, M. O., Horvath, T. L., Sinclair, D. A., Pfluger, P. T., & Tschöp, M. H. (2012) · Physiological Reviews · doi:10.1152/physrev.00022.2011 · Cited by 711
Redox regulation of mitochondrial function
Handy, D. E., & Loscalzo, J. (2012) · Antioxidants & Redox Signaling · doi:10.1089/ars.2011.4123 · Cited by 588
“A more recent study used pharmacological methods to induce the oxidation of NADH by the cytosolic NADH:quinone oxidoreductase 1 (NQ1) (183).”
MethodThe diverse functionality of NQO1 and its roles in redox control
Ross, D., & Siegel, D. (2021) · Redox Biology · doi:10.1016/j.redox.2021.101950 · Cited by 499
Foxo1 integrates insulin signaling with mitochondrial function in the liver
Cheng, Z., Guo, S., Copps, K., Dong, X., Kollipara, R., Rodgers, J. T., Depinho, R. A., Puigserver, P., & White, M. F. (2009) · Nature Medicine · doi:10.1038/nm.2049 · Cited by 321
“Pharmacological stimulation of mitochondrial NADH oxidation dramatically promotes fatty acid oxidation and ameliorates dyslipidemia, adiposity and fatty liver in obese mic”
Ross, D., & Siegel, D. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.00595 · Cited by 317
Metabolic reprogramming, caloric restriction and aging
Anderson, R. M., & Weindruch, R. (2010) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2009.11.005 · Cited by 301
Redox implications in adipose tissue (dys)function-A new look at old acquaintances
Jankovic, A., Korac, A., Buzadzic, B., Otasevic, V., Stancic, A., Daiber, A., & Korac, B. (2015) · Redox Biology · doi:10.1016/j.redox.2015.06.018 · Cited by 91
Lee, E.-J., Ko, H.-M., Jeong, Y.-H., Park, E.-M., & Kim, H.-S. (2015) · Journal of Neuroinflammation · doi:10.1186/s12974-015-0355-z · Cited by 91
“In addition, βLAP has beneficial effects on metabolic syndromes such as obesity, diabetes, hypertension, arterial restenosis, and salt-induced renal injury [45–48].”
Metadata
- Authors
- Hwang, J. H., Kim, D. W., Jo, E. J., Kim, Y. K., Jo, Y. S., Park, J. H., Yoo, S. K., Park, M. K., Kwak, T. H., Kho, Y. L., Han, J., Choi, H.-S., Lee, S.-H., Kim, J. M., Lee, I., Kyung, T., Jang, C., Chung, J., Kweon, G. R., & Shong, M.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2009-01-09
- Volume
- 58
- Issue
- 4
- Pages
- 965-974
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2142699482
- Cited by
- 133
- References
- 22
- FWCI
- 5.72
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.